thecardiologyadvisor.com1h
FDA Drug Approval Decisions Expected in March 2025
The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
FDA approves new genetic disorder drug
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
FDA approves SpringWorks’ mirdametinib for adult and pediatric NF1 patients
The Food and Drug Administration approved mirdametinib, brand name Gomekli, from SpringWorks Therapeutics (SWTX), a kinase inhibitor, for adult ...
STAT19h
Judge tells agencies to restore webpages and data removed after Trump’s executive order
A federal judge on Tuesday ordered government agencies to restore public access to health-related webpages and datasets that ...
US FDA approves SpringWorks' genetic disorder drug
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...